Enterprise Value

186.2M

Cash

52.72M

Avg Qtr Burn

-11.41M

Short % of Float

7.42%

Insider Ownership

8.39%

Institutional Own.

33.85%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Arimoclomol (Heat-Shock Protein (HSP) amplifier) Details
Rare genetic disease, Rare diseases, Niemann Pick Disease Type C

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Celiprolol Details
Vascular Ehlers-Danlos Syndrome

Phase 3

Data readout

KP1077 (serdexmethylphenidate, SDX) Details
EDS in Idiopathic Hypersomnia

Phase 2

Update

Phase 1

Data readout

KP879 (Methylphenidate) Details
Stimulant Use Disorder

Phase 1

Update